See more : Digitree Group S.A. (DTR.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Mallinckrodt plc (MNK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mallinckrodt plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- ASSA ABLOY AB (publ) (ASSA-B.ST) Income Statement Analysis – Financial Results
- ABL Group ASA (AQUA.OL) Income Statement Analysis – Financial Results
- Finance For Food S.R.L. (FFF.MI) Income Statement Analysis – Financial Results
- AAC Clyde Space AB (publ) (0GFN.L) Income Statement Analysis – Financial Results
- PT Kedoya Adyaraya Tbk (RSGK.JK) Income Statement Analysis – Financial Results
Mallinckrodt plc (MNK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mallinckrodt.com
About Mallinckrodt plc
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21B | 2.21B | 2.21B | 3.16B | 3.22B | 3.22B | 3.38B | 3.35B | 2.54B | 2.21B | 2.06B | 2.02B |
| Cost of Revenue | 1.32B | 1.32B | 1.54B | 1.74B | 1.74B | 1.57B | 1.53B | 1.49B | 1.34B | 1.18B | 1.09B | 1.11B |
| Gross Profit | 891.70M | 891.70M | 669.40M | 1.42B | 1.47B | 1.66B | 1.86B | 1.85B | 1.20B | 1.03B | 964.80M | 914.90M |
| Gross Profit Ratio | 40.37% | 40.37% | 30.24% | 44.95% | 45.75% | 51.41% | 54.87% | 55.38% | 47.36% | 46.62% | 46.92% | 45.25% |
| Research & Development | 205.20M | 205.20M | 290.80M | 349.40M | 361.10M | 277.30M | 262.20M | 185.10M | 166.90M | 166.50M | 144.10M | 141.50M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 581.80M | 581.80M | 884.10M | 831.00M | 834.10M | 920.90M | 925.30M | 1.17B | 842.10M | 611.40M | 551.70M | 532.50M |
| Other Expenses | 0.00 | 22.00M | 7.40M | 63.60M | 30.90M | 6.00M | -600.00K | 8.10M | 1.80M | 800.00K | 1.00M | 2.90M |
| Operating Expenses | 787.00M | 787.00M | 1.17B | 1.18B | 1.20B | 1.20B | 1.19B | 1.35B | 1.01B | 777.90M | 695.80M | 674.00M |
| Cost & Expenses | 2.10B | 2.10B | 2.72B | 2.92B | 2.94B | 2.76B | 2.71B | 2.85B | 2.35B | 1.96B | 1.79B | 1.78B |
| Interest Income | 1.90M | 1.90M | 5.90M | 9.50M | 8.20M | 4.60M | 1.30M | 1.00M | 1.50M | 300.00K | 400.00K | 200.00K |
| Interest Expense | -222.60M | 222.60M | 261.10M | 309.00M | 370.20M | 369.10M | 384.60M | 255.60M | 82.60M | 19.50M | 500.00K | 600.00K |
| Depreciation & Amortization | 328.90M | 675.80M | 885.20M | 951.10M | 852.10M | 808.30M | 834.50M | 672.50M | 275.90M | 139.60M | 130.90M | 119.80M |
| EBITDA | -723.50M | 804.40M | 393.00M | 1.27B | 1.17B | 468.70M | 1.50B | 1.18B | 473.30M | 254.30M | 401.30M | 363.80M |
| EBITDA Ratio | -32.76% | 36.42% | 17.76% | 40.01% | 36.30% | 14.55% | 44.45% | 35.27% | 18.63% | 11.50% | 19.52% | 17.99% |
| Operating Income | -1.05B | 128.60M | -492.20M | 314.10M | -3.72B | 420.10M | 617.30M | 461.80M | -284.10M | 148.70M | 235.20M | 240.70M |
| Operating Income Ratio | -47.65% | 5.82% | -22.24% | 9.93% | -115.71% | 13.04% | 18.26% | 13.80% | -11.18% | 6.72% | 11.44% | 11.91% |
| Total Other Income/Expenses | 222.60M | -958.40M | -468.60M | -1.91B | -331.10M | -358.50M | -383.90M | -246.50M | -79.30M | -18.40M | 900.00K | 2.50M |
| Income Before Tax | -829.80M | -829.80M | -960.80M | -1.59B | -4.05B | 61.60M | 233.40M | 215.30M | -363.40M | 130.30M | 236.10M | 243.20M |
| Income Before Tax Ratio | -37.57% | -37.57% | -43.41% | -50.32% | -126.01% | 1.91% | 6.90% | 6.43% | -14.30% | 5.89% | 11.48% | 12.03% |
| Income Tax Expense | -112.40M | -106.30M | 8.90M | -584.30M | -430.10M | -1.71B | -255.60M | -92.90M | -44.80M | 70.20M | 94.80M | 86.20M |
| Net Income | -717.40M | -723.50M | -969.70M | -1.01B | -3.61B | 2.13B | 643.70M | 324.70M | -319.30M | 61.10M | 134.60M | 150.70M |
| Net Income Ratio | -32.48% | -32.76% | -43.81% | -31.85% | -112.17% | 66.25% | 19.04% | 9.70% | -12.57% | 2.76% | 6.55% | 7.45% |
| EPS | -8.47 | -8.54 | -11.48 | -12.00 | -42.94 | 21.85 | 5.82 | 2.78 | -4.92 | 1.06 | 2.33 | 2.61 |
| EPS Diluted | -8.47 | -8.54 | -11.48 | -12.00 | -42.94 | 21.80 | 5.77 | 2.75 | -4.92 | 1.06 | 2.33 | 2.61 |
| Weighted Avg Shares Out | 84.70M | 84.70M | 84.50M | 83.90M | 84.00M | 97.70M | 110.60M | 115.80M | 64.90M | 57.70M | 57.70M | 57.70M |
| Weighted Avg Shares Out (Dil) | 84.70M | 84.70M | 84.50M | 83.90M | 84.00M | 97.90M | 111.50M | 117.20M | 64.90M | 57.80M | 57.70M | 57.70M |
Mallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring Plan
Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar® Gel (Repository Corticotropin Injection)
Buxton Helmsley Issues Statement on Mallinckrodt plc. Bankruptcy Filing and Disclosures Revealing Apparently Concealed Intangible Asset Depreciation Expenses
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
MNK Investors Have Opportunity to Lead Mallinckrodt plc Securities Fraud Lawsuit
Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations
NYSE American to Commence Delisting Proceedings Against Mallinckrodt plc (MNK)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK
Source: https://incomestatements.info
Category: Stock Reports